Group 1 - Worldwide Clinical Trials has entered a definitive agreement to acquire Catalyst Clinical Research, an oncology contract research organization (CRO) [1] - The acquisition aims to establish Worldwide as an oncology-focused CRO while expanding its global reach for clinical trials and maintaining depth in several therapeutic areas [2][3] - Catalyst's Board chairman Nick Dyer will join Worldwide's board, and Catalyst's president and CEO Nik Morton will become part of Worldwide's executive leadership team [1][4] Group 2 - The integration will combine Catalyst's solutions, including Catalyst Flex and Catalyst Oncology, with Worldwide's existing portfolio, enhancing service offerings for full-service and functional service provider (FSP) resourcing [2] - The deal includes the adoption of complementary technology platforms and operational practices to improve data efficiency and visibility across the development lifecycle [3] - The transaction is expected to conclude in Q1 2026, pending customary closing conditions and regulatory approvals [3] Group 3 - Worldwide is backed by Kohlberg, while Catalyst is a portfolio company of QHP Capital [4] - Worldwide CEO Alistair Macdonald emphasized that the merger will elevate capabilities in oncology and provide new solutions for customers [4][5] - The combined entity will offer a scalable FSP model with integrated onshore/offshore service lines, leveraging advanced business management tools and AI for operational excellence [5][6]